CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
estrogens, conjugated +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000466
NCT00000466Phase 3Completed

Postmenopausal Estrogen/Progestin Interventions (PEPI)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated May 13, 2016

In Brief

A Phase 3 clinical trial evaluating estrogens, conjugated, medroxyprogesterone, and 2 other interventions for Bone Diseases and 10 related conditions. Completed.

Detailed Summary

To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.

Study Details

Timeline

Phase 3CompletedFinished
19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartSep 1, 1987
Study CompletionOct 1, 2000
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

estrogens, conjugateddrug

medroxyprogesteronedrug

progesteronedrug

estrogen replacement therapydrug